Pharmaceutical Technology

MAY 19, 2023

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Prospecting 98

Prospecting Marketing Patients Leads 98

Pharmaceutical Technology

DECEMBER 5, 2022

Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database. This is closely followed by CB2 receptors in second place.

Medical 98

Medical Specialization Marketing Leads 98

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. However, more highly innovative/high-cost treatments, within infectious disease and neurology space, are likely to enter the market for rare disorders, increasing the number of non-oncology RSAs.

Marketing 105

Marketing Medicine Leads Safety 105

Pharmaceutical Technology

MAY 2, 2023

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy.

Physicians 52

Physicians Marketing Patients Manufacturing 52

PM360

SEPTEMBER 7, 2023

Then onto Tuan Vu, MD, Professor of Neurology, Director, Neuromuscular Division, EMG Laboratories, and ALS Clinic, Department of Neurology University of South Florida, who discussed the global clinical trial. We also put big pull tags on the little pouches that held the items.

Patients 105

Patients Pharma Education Doctors 105

European Pharmaceutical Review

MAY 11, 2023

1 This is assuming a $1M price tag for all gene therapies. Internet] NIH National Institute of Neurological Disorders and Stroke. What are the emerging modalities in the gene therapy sector? By 2030, 20-25 gene therapies are expected to reach market approval, accounting for 1.30-1.61 percent of Europe’s annual healthcare spend.

Food and Drug Administration 71

Food and Drug Administration Government Healthcare Healthcare 71

Pharmaceutical Technology

JANUARY 27, 2023

James George, a research professor at the University of Oklahoma Health Sciences Center, said Cablivi “adds a new aspect to treatment, the prompt recovery of platelets and prompt resolution of transient neurologic symptoms”. In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry.

Patients 52

Patients Pharmaceutical Manufacturing Healthcare Provider 52